EPIDIOLEX
Total Payments
$9.0M
Transactions
29,007
Doctors
5,759
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.4M | 10,544 | 3,369 |
| 2023 | $3.2M | 9,792 | 3,013 |
| 2022 | $2.4M | 8,670 | 2,713 |
| 2021 | $14.86 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.2M | 2,585 | 57.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.9M | 690 | 21.1% |
| Food and Beverage | $764,117 | 24,647 | 8.5% |
| Consulting Fee | $398,019 | 148 | 4.4% |
| Grant | $278,500 | 3 | 3.1% |
| Travel and Lodging | $225,099 | 883 | 2.5% |
| Space rental or facility fees (teaching hospital only) | $191,000 | 41 | 2.1% |
| Royalty or License | $75,000 | 1 | 0.8% |
| Education | $576.22 | 9 | 0.0% |
Payments by Type
Research
$5.2M
2,585 transactions
General
$3.8M
26,422 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A LONG-TERM SAFETY STUDY TO ASSESS THE POTENTIAL FOR CHRONIC LIVER INJURY IN PARTICIPANTS TREATED WITH EPIDIOLEX (CANNABIDIOL) ORAL SOLUTION | JAZZ PHARMACEUTICALS INC. | $627,189 | 1 |
| A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution | JAZZ PHARMACEUTICALS INC. | $620,331 | 0 |
| AN EXPLORATORY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE SAFETY AND EFFICACY OF CANNABIDIOL ORAL SOLUTION (GWP42003-P; CBD-OS) IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORD | JAZZ PHARMACEUTICALS INC. | $538,537 | 0 |
| AN EXPLORATORY PHASE 2 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE SAFETY AND EFFICACY OF CANNABIDIOL ORAL SOLUTION (GWP42003-P; CBD-OS) IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORD | JAZZ PHARMACEUTICALS INC. | $509,794 | 1 |
| An Exploratory, Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disord | JAZZ PHARMACEUTICALS INC. | $349,673 | 0 |
| A Randomized, Double-blind, Placebo-controlled, Multisite, Phase 3 Study to Investigate the Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P) in Children and Adolescents With Epilepsy With Myoclonic-Atonic Seizures | JAZZ PHARMACEUTICALS INC. | $313,189 | 0 |
| EPIDIOLEX FOR THE TREATMENT OF ANXIETY COMORBIDITY IN REFRACTORY PEDIATRIC EPILEPSY | JAZZ PHARMACEUTICALS INC. | $262,616 | 0 |
| A RANDOMIZED DOUBLE-BLIND PARALLEL-GROUP TRIAL TO INVESTIGATE THE SAFETY AND EFFICACY OF GWP42003-P VERSUS PLACEBO AS ADJUNCTIVE THERAPY IN PARTICIPANTS WITH SCHIZOPHRENIA EXPERIENCING INADEQUATE RESPONSE TO ONGOING ANTIPSYCHOTIC TREATMENT | JAZZ PHARMACEUTICALS INC. | $250,088 | 0 |
| A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF CANNABIDIOL (GWP42003-P CBD) AS ADD PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX WHO EXPERIENCE INADEQUATELY-CONTROLLED SEIZURES | JAZZ PHARMACEUTICALS INC. | $247,935 | 0 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTISITE, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF CANNABIDIOL ORAL SOLUTION (GWP42003-P) IN CHILDREN AND ADOLESCENTS WITH EPILEPSY WITH MYOCLONIC-ATONIC SEIZURES | JAZZ PHARMACEUTICALS INC. | $191,356 | 0 |
| An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Participants With Tuberous Sclerosis Complex (Age 1 Month to < 2 Years of Age), Dravet Syndrome (1 Year to < 2 Years of Age), or Lennox-Gastaut Syndrome (1 Year to < 2 Years of Age) Who Experience Inadequately-controlled Seizures | JAZZ PHARMACEUTICALS INC. | $178,906 | 0 |
| Identifying Patients With Uncommon Epilepsy Symptoms, Assessing Treatment Outcomes, And Enhancing Quality Of Life | JAZZ PHARMACEUTICALS INC. | $161,690 | 0 |
| SAFETY AND EFFICACY OF CBD (EPIDIOLEX) IN IDIOPATHIC GENERALIZED EPILEPSY WITH TYPICAL ABSENCE SEIZURES | JAZZ PHARMACEUTICALS INC. | $148,717 | 0 |
| A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF CANNABIDIOL (GWP42003-P CBD) AS ADD-ON THERAPY IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX WHO EXPERIENCE INADEQUATELY-CONTROLLED SEIZURES | JAZZ PHARMACEUTICALS INC. | $146,072 | 0 |
| AN OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE SAFETY OF CANNABIDIOL (GWP42003-P; CBD) IN CHILDREN AND ADULTS WITH INADEQUATELY CONTROLLED DRAVET OR LENNOX-GASTAUT SYNDROMES | JAZZ PHARMACEUTICALS INC. | $119,718 | 0 |
| HUMAN EPILEPSY PROJECT 3: NEWLY DIAGNOSED IDIOPATHIC GENERALIZED EPILEPSY | JAZZ PHARMACEUTICALS INC. | $115,444 | 0 |
| NOVEL COGNITIVE TREATMENT TARGETS FOR EPIDIOLEX IN STURGE- WEBER SYNDROME: A PHASE II TRIAL | JAZZ PHARMACEUTICALS INC. | $62,500 | 0 |
| EFFICACY OF EPIDIOLEX IN PATIENTS WITH ELECTRICAL STATUS EPILEPTICUS OF SLEEP (ESES) | JAZZ PHARMACEUTICALS INC. | $57,410 | 0 |
| Establishment of a registry to study patients prospective | JAZZ PHARMACEUTICALS INC. | $48,333 | 0 |
| AN OPEN-LABEL EXPLORATORY INVESTIGATION OF COGNITIVE OUTCOMES WITH CANNABIDIOL ORAL SOLUTION (EPIDIOLEX GWP42003-P) | JAZZ PHARMACEUTICALS INC. | $44,597 | 0 |
Top Doctors Receiving Payments for EPIDIOLEX — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , NP | Nurse Practitioner | New York, NY | $33,123 | 72 |
| , MD | Clinical Neurophysiology | Los Angeles, CA | $32,838 | 27 |
| , MD | Epilepsy | Cincinnati, OH | $31,784 | 28 |
| , MD | Neurology | New York, NY | $28,292 | 76 |
| , M.D | Neurology | Atlanta, GA | $27,594 | 55 |
| , M.D | Epilepsy | Tampa, FL | $27,561 | 51 |
| , FNP-BC | Family | Wichita, KS | $27,177 | 61 |
| , MD | Neurology with Special Qualifications in Child Neurology | Evanston, IL | $25,816 | 30 |
| , M.D | Pediatrics | Roseville, MN | $23,264 | 20 |
| , MD | Neurology | New Orleans, LA | $23,215 | 44 |
| , M.D | Epilepsy | Carlsbad, CA | $23,194 | 46 |
| , MD | Neurology | Albany, NY | $22,802 | 20 |
| , M.D | Neurology | Birmingham, AL | $21,831 | 19 |
| , M.D | Neuromusculoskeletal Medicine & OMM | Marietta, GA | $21,688 | 41 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Chattanooga, TN | $21,307 | 57 |
| , M.D | Neurology | Phoenix, AZ | $21,101 | 33 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Houston, TX | $20,052 | 34 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Cleveland, OH | $19,071 | 13 |
| , MD | Neurology | Saint Paul, MN | $18,632 | 15 |
| , M.D | Pediatrics | Madera, CA | $17,626 | 49 |
| , MD PHD | Neurology with Special Qualifications in Child Neurology | Boston, MA | $17,467 | 18 |
| , MD | Neurology with Special Qualifications in Child Neurology | Augusta, GA | $17,420 | 41 |
| , M.D | Neurology | Atlanta, GA | $15,504 | 24 |
| , MD | Neurology with Special Qualifications in Child Neurology | Gulf Breeze, FL | $14,461 | 18 |
| , M.D | Gastroenterology | Indianapolis, IN | $14,300 | 19 |
Ad
Manufacturing Companies
- JAZZ PHARMACEUTICALS INC. $8.6M
- Jazz Pharmaceuticals Inc. $416,944
Product Information
- Type Drug
- Total Payments $9.0M
- Total Doctors 5,759
- Transactions 29,007
About EPIDIOLEX
EPIDIOLEX is a drug associated with $9.0M in payments to 5,759 healthcare providers, recorded across 29,007 transactions in the CMS Open Payments database. The primary manufacturer is JAZZ PHARMACEUTICALS INC..
Payment data is available from 2021 to 2024. In 2024, $3.4M was paid across 10,544 transactions to 3,369 doctors.
The most common payment nature for EPIDIOLEX is "Unspecified" ($5.2M, 57.6% of total).
EPIDIOLEX is associated with 20 research studies, including "A LONG-TERM SAFETY STUDY TO ASSESS THE POTENTIAL FOR CHRONIC LIVER INJURY IN PARTICIPANTS TREATED WITH EPIDIOLEX (CANNABIDIOL) ORAL SOLUTION" ($627,189).